Rationale Recent studies have shown that cannabis may disrupt glutamate (Glu) signaling depressing Glu tone in frequent users. Current evidence have also consistently reported lower Glu-levels in various brain regions, particularly in the medial prefrontal cortex (mPFC) of chronic schizophrenia patients, while findings in early psychosis (EP) are not conclusive. Since cannabis may alter Glu synaptic plasticity and its use is a known risk factor for psychosis, studies focusing on Glu signaling in EP with or without a concomitant cannabis-usage seem crucial.
Introduction
Δ9-tetrahydrocannabinol (THC), the primary psychoactive cannabinoid present within cannabis, exerts its effect by binding the cannabinoid receptors type 1 (CB1R) that are widely distributed in the brain. Consequently, the long-term use of cannabis might cause alterations in both morphology and function of brain regions rich in CB1R (i.e., prefrontal cortex, hippocampus, amygdala, cerebellum), but so far findings are still controversial (Lorenzetti et al. 2015) . If the impact of cannabis use on brain structure is largely investigated, still little is known about the effect of cannabis on brain tissue's neurochemical profiles. Proton magnetic resonance spectroscopy ( 1 H MRS), is a non-invasive measurement technique that enables the in vivo detection of a wide range of neurometabolites including neurotransmitters. Among them, glutamate (Glu) could be considered as a promising candidate to capture the effects of cannabis on the brain (for a review see Colizzi et al. 2016) . There is indeed a large body of evidence accumulated from animal studies demonstrating that in vivo administration of THC affects the release of Glu in the prefrontal cortex (PFC), and that this process is mediated by CB1R (Pistis et al. 2001) . Specifically, the administration of THC depresses endocannabinoid-mediated glutamatergic synaptic transmission, affecting the release, the enzyme activity, and the expression of both Glu-receptors and transporters (Colizzi et al. 2016) . Also, prolonged THC exposure affects Glu synaptic plasticity by a functional tolerance mechanism, reducing the ability of CB1R-agonists to inhibit Glu synaptic transmission (Mato et al. 2005) .
The application of MRS to investigate the effect of cannabis in humans, although limited by the paucity of studies, tends to replicate findings of animal models. To the best of our knowledge, only four authors examined in vivo Glurelated metabolites levels in cannabis users, while only one prior study focused on a population of schizophrenia patients with a concomitant cannabis usage. Lower levels of Glu, Nacetylaspartate (NAA), and myo-inositol (mIns) were observed in regular cannabis users without a psychiatric disorder compared to control subjects, in regions known to be associated with substance use: including the dorsal striatum in 27 subjects (Muetzel et al. 2013) , the anterior cingulate cortices in 17 and 13 cannabis users, respectively (Prescot et al. 2011 (Prescot et al. , 2013 , and the basal ganglia and thalamus in 24 individuals without psychosis (Chang et al. 2006) . The only study focusing on patients with schizophrenia found a specific effect of substance use on reducing levels of Glu plus Glutamine (Gln) (Bernier et al. 2016) .
The impact of THC on Glu-signaling is of considerable interest as it offers a possible key to unravel the neurobiological substrate of the clinical phenotype of cannabis-associated psychosis. Supporting an integrated hypothesis, several lines of evidences point indeed to there being an hypo-functioning Glu neurotransmission leading to the presynaptic dopamine dysfunction consistently reported in schizophrenia, which may provide the best explanation of all the clinical aspects of this heterogeneous and complex disorder (Howes et al. 2015) . Furthermore, recent studies have shown decreased Glu levels in schizophrenia patients when compared to healthy individuals, particularly in medial frontal region (Marsman et al. 2013) . Moreover, chronicity in schizophrenia was found to be related to decreased prefrontal Glu (Natsubori et al. 2014) , Glx (Glu + Gln) and NAA levels (Liemburg et al. 2016) ; with evidence for a time-depending role for Glu (Merritt et al. 2016) , whereas findings in early psychosis (EP) are still controversial (for a review see Treen et al. 2016) . While the studies presented above provide evidence that THC leads to glutamatergic dysfunction, they do not unequivocally identify the specific brain circuits or regions involved. The PFC has been suggested, among others, as a potential target-site as glutamatergic projections to the midbrain regulate midbrain dopamine neurons (Howes et al. 2015) . Furthermore, the prefrontal cortical and subcortical changes in metabolism occurring within cannabis users are thought to disturb prefrontal cortical maturation, which could ultimately give rise to neurobiological impairments (Zamberletti et al. 2014; Rubino et al. 2015) .
THC seems therefore to have the potential to disrupt the normal interplay between neurotransmitters in PFC, particularly Glu, and may bear relevance in understanding THCassociated cognitive and clinical dimensions. The aim of the present study was to employ 1 H MRS for investigating Glu levels in the mPFC of EP cannabis users compared with their non-using counterpart and normative healthy controls.
Based on this background we hypothesized:
(i) a reduced glutamate level in EP subjects who used cannabis compared to EP non-users and healthy controls, respectively (ii) the absence of a difference between EP non-users and HC in terms of [Glu mPFC ] (iii) a correlation between level of cognitive deficits in EP users and pre-frontal glutamatergic dysfunction
Method Subjects
Thirty-five EP subjects, of whom 18 were currently cannabis users, were recruited from the Treatment and Early Intervention in Psychosis Program (TIPP), of the University Hospital in Lausanne (Baumann et al. 2013 ). The TIPP is a specialized 3-year early psychosis programme. Entry criteria to the program are (i) age between 18 and 35 years; (ii) residence in the catchment area (Lausanne and surrounding); (iii) meeting threshold criteria for psychosis, as defined by the 'Psychosis threshold' subscale of the Comprehensive Assessment of At Risk Mental States (CAARMS) (Yung et al. 2005) ; and (iv) not more than 6 months of treatment with antipsychotic medication for the psychotic disorder. The CAARMS is a clinical tool to assess if subjects meet criteria for being at ultra-high risk for onset of first psychotic disorder. The BPsychosis threshold^subscale allows assessing if a subject fulfills criteria for a Bfull blown^psychotic episode. The diagnostic assessment for TIPP patients is the result of an expert consensus and is based on the following elements: (Andreasen et al. 2010 ) diagnosis reported by treating psychiatrist in all medical documents and at the end of any hospitalization; (Arseneault et al. 2002) longitudinal assessment by clinical case managers over the 3 years of treatment. The consensus diagnosis procedure realized by a senior psychiatrist and the senior psychologist who is in charge of scale-based assessment over the treatment period. They both review the entire file once after 18 months and again after 36 months or at the end of treatment and conduct a diagnostic process based on DSM-IV criteria (APA 1994) discussing any unclear issue with the clinical case manager. In this paper, only the final diagnosis, defined at the end of TIPP treatment period, is considered. Thirty-three healthy controls matched on gender, age, and handedness were recruited from similar geographic and socio-demographic areas and assessed by the Diagnostic Interview for Genetic Studies (Preisig et al. 1999) . Major mood, psychotic, or substance-use disorder and having a first-degree relative with a psychotic disorder were exclusion criteria for controls. Neurological disorders and severe head trauma were exclusion criteria for all subjects. 31 of the 35 patients were on antipsychotic medication at the time of this study, with an average medication of 329.3 ± 212.1 mg chlorpromazine equivalent dose (CPZ) (Andreasen et al. 2010 ) ( Table 1) . Informed written consent in accordance with our institutional guidelines (protocol approved by the Ethic Committee of Lausanne University) was obtained for all the subjects.
Assessment of cannabis use
A detailed history of illicit drug use (cannabis, stimulants and any other recreational drug) was taken using a specially designed questionnaire (the TIPP Initial Assessment Tool: TIAT). This allows a detailed assessment of lifetime patterns of cannabis use, including frequency and duration of use and age at first use. The measures of exposure to cannabis use included in the analyses were (a) current cannabis use (is the subject currently using cannabis: no = 0; yes = 1); (b) lifetime frequency of cannabis use [the frequency that characterized the subject's most consistent pattern of use: at weekends or less frequently (occasional) = 0; every day (daily) = 1]; and (c) age at first use (the age when the subject started to use cannabis regularly: prior to age 15 years = 0; above age 15 years = 1). This cut-off was based on previous studies showing an increased risk of mental health disorders in users of cannabis before the age of 15 (Arseneault et al. 2002; Fontes et al. 2011) . On the basis of this data, EP patients were dichotomised between (a) regular cannabis users and (b) occasional users.
Neuropsychological assessment
Neuropsychological assessment was made according to the H MRS measurements were performed on the 3T MR scanner (Magnetom TimTrio, Siemens Healthcare, Erlangen, Germany) with a transverse electromagnetic (TEM 3000) head coil (MR Instruments, Inc). The magnetic field homogeneity was optimized by adjusting first-and second-order shims using FAST(EST)MAP (Gruetter 1993; Gruetter and Tkac 2000) . In vivo 1H MR spectra were acquired from the medial prefrontal cortex (mPFC; Fig. 1a ) using a short-TE spin-echo full-intensity acquired localized single voxel spectroscopy technique (SPECIAL) (Mekle et al. 2009; Mlynarik et al. 2006) . Outer volume suppression (OVS) (Tkac et al. 2001) and water suppression with variable-pulse power and optimized relaxation delays (VAPOR) (Tkac et al. 1999) were applied prior to the SPECIAL localization sequence. The following scan parameters were used: volume of interest (VOI = 20 × 20 × 25 mm3), echo time/repetition time (TE/ TR) = 6/4000 ms, acquisition bandwidth = 2 kHz, number of averages = 148, vector size = 2.
Spectral quantification
To obtain [Glu mPFC ] water suppressed in vivo, 1 H MR s p e c t r a w e r e a n a l y z e d b y L C M o d e l ( S t e p h e n Provencher, Inc) using a basis-set consisting of 20 simulated individual metabolite spectra: alanine (Ala), aspartate (Asp), phosphocreatine (PCr), creatine (Cr), γ-aminobutyric acid (GABA), glutamine (Gln), glutam a t e ( G l u ) , p h o s p h o r y l c h o l i n e ( P C h o ) , glycerophosphorylcholine (GPC), gluthathione (GSH), glucose (Glc), lactate (Lac), glycine (Gly), myo-inositol ( m I n s ) , N -a c e t y l a s p a r t y l g l u t a m a t e ( N A A ) , Nacetylaspartylglutamate (NAAG), ascorbate (Asc), phosphoryl-ethanolamine (PE), scylloinositol (Scyllo), taurine (Tau), and an experimentally measured macromolecule baseline. Unsuppressed water 1H MR spectra were used as an internal reference for the absolute quantification of metabolite concentrations. Tissue composition inside the MRS volume used for water content calculation and partial volume correction was calculated based on the segmentation of magnetization-prepared rapid gradientecho (MPRAGE) (Mugler and Brookeman 1990) images (TE/TR = 2.98/2300 ms, TI = 900 ms, flip angle = 9 degree, FOV = 240 × 256 mm2, matrix = 240 × 256, slice thickness = 1.2 mm) MPRAGE images using an in-house software (more details are reported elsewhere, Xin et al. 2016 ).
Statistical analysis
Statistical analyses were performed with SPSS (SPSS, Chicago, Illinois). Differences between groups in sociodemographics and clinical characteristics were assessed with Chi-square or T test as appropriate. To investigate the effect of cannabis on prefrontal Glu levels, an univariate analyses of covariance (ANCOVAs) was used, with mean [Glu mPFC ] entered as dependent variable, group as fixed factor (EP-users; EP non-users and HC); age and gender as covariates of no interest. To examine the effect of cannabis across the users' sample, the same analyses were performed with frequency of use (never or occasional vs. daily), and age at first use (< or > 15 years) separately entered as fixed factors. The same analyses were repeated entering alcohol use, number of cigarettes smoked and medication (CPZ equivalents) as nuisance variables. Analyses performed for Gln, NAA and GABA are shown in Supplementary materials. Differences in neuropsychological measures between EPusers, non-users, and controls were investigated using a multivariate analysis of covariance (MANCOVA).
Finally, correlations between mean Glu mPFC values and cognitive measures were tested with Pearson's correlation coefficient. The correlation analyses were performed only on neuropsychological domain that differentiate within patients depending on their cannabis usage. A Fisher r-to-z transformation of the correlation coefficients was used to compare the strength of the correlations between groups. (Calculation for the test of the difference between 2 independent correlation coefficients is available from http://quantpsy.org). 
Socio-demographic characteristics
There were no significant differences in age, gender, and handedness between EP subjects and HC, indicating that patients and controls were well matched for these factors. As expected, patients had a lower level of education than controls (t = 4.88, p = 0.001). PANSS was similar for the two groups, with EP users having 62.7(17.7) and EP nonusers 64.1(15.8) mean total PANSS score [t = −.26 p = 0.7]. At 36 months follow-up within the users, 11 patients were diagnosed with schizophrenia, 4 with brief psychotic disorder, 3 with schizoaffective disorder. Among the non-users group, 9 patients were diagnosed with schizophrenia, 4 with schizoaffective disorder; 2 with bipolar disorder and another 2 with brief psychotic disorder. Main clinical characteristics are presented in Table 1 .
Cannabis and patterns of use 51.4% (N = 18) of patients were currently cannabis users, 10 among them were occasional users (used weekly or less), and another 8 were daily users (daily usage or more than 3 times per week). The mean age at onset of cannabis use were 17 ± 4.5 years, with cannabis users being more likely alcohol users [χ2(4,5), p = 0.02] and cigarettes smokers [(χ2(18,2) , p < 0.001]) compared to non-users. There were no statistical differences in age, gender, medication (Cpz equivalents) and duration of illness between the two groups (users Vs non-users). EP users had a lower level of education than non-users (t = 3.82, p = 0.001). Other drugs (cocaine, stimulants, heroine, and opioids) were minimally used, with 1 EP users having a concomitant, sporadic use of cocaine. Within the EP non-users group there was only 1 subject who had used cannabis in the past, occasionally and during 3 years, but who had stopped smoking two years before entering the study.
Neuropsychological performance
Complete neuropsychological performances are detailed in Table 2 . As expected, neuropsychological performances were deeply affected in patients as compared to healthy controls particularly when considering EP users, while a less cognitive impairment was observed in EP non-users F(2.57)=; p < 0.001; d = 0.51. Working memory was the only domain found to be impaired in EP users compared to their non-using counterpart, and that entered the subsequent correlative analyses. Patterns of cannabis use were not significantly related to any cognitive measures; age at which regular cannabis use commenced did not have a significant effect either.
[GLU mPFC ] and cannabis use [Glu mPFC ] was measured by short-TE 1 H MRS at 3T and quantified using LCModel with CRLBs of 2.0 ± 0.5% (mean ± SDMean). [Glu mPFC ] levels in EP users were significantly lower (12.7 ± 1.3 μmol/g) than in both EP non-users (13.9 ± 1.5 μmol/g) and HC (14.2 ± 0.9 μmol/g), [F(4.66) = 7.1; p = 0.002] with a medium effect size of d = 0.4. Bonferroni post-hoc tests showed a significant reduction on [Glu mPFC ] levels between EP-users and healthy controls (p = 0.001) and also between EP users and EP non-users (p = 0.013); while controls and EP non-users did not differ (p = 0.9).
When alcohol and cigarette intake, as well as medication (CPz equivalents) was set as nuisance factors in the model, all results retain their statistical significance.
Patterns of use did not significantly affect [Glu mPFC ] levels [F(4,16) = 0,1; p = 0.7], albeit every day users having a slightly lower mean [Glu mPFC ] levels (12.5 ± 1.3 μmol/g) than occasional users (13.2 ± 0.9 μmol/g), respectively. Finally, we evaluated the effect of age at first use, and found no significant differences in mean [Glu mPFC ] levels between early (< 15 years) and late onset cannabis users (> 15 years) (Fig. 2) .
Correlation between [GLU mPFC ] and clinical characteristics
[GLU mPFC ] levels were not related to mean duration of illness (r = − 11, p = 0.3), and neither to PANSS total scores (r = − 0.4; p = 0.4). CPZ equivalents displayed a significant positive association with [GLU mPFC ] (r = .34; p = 0.03).
Correlation between [GLU mPFC ] and working memory
In the sample as a whole (both EP and controls), mean [GLU mPFC ] levels positively correlate with working memory (WM) (r = .37, p = 0.002). When running correlations separately for each group, this correlation still remains significant in controls (r = .43; p = 0.01) but not in EP non-users or EP users. After controlling for age and years of education, results maintain significance. EP users and controls demonstrate, at trend level, differences in correlation coefficients of [GLU mPFC ] with WM (z = 1.4, p = 0.07) (Fig. 3) .
Correlations between mean Glu mPFC and age
Age was significantly negatively associated with mean [Glu mPFC ] levels in the combined sample (r = −.30; p = 0.006) and independently in EP (r = − .36; p = 0.02).
Within patients, the [Glu mPFC ]-decline with age was found in EP users (r = − .46; p = 0.04) but not in EP non-users. In EP users, these results remain significant when controlling for Cpz equivalents (Fig. 4) .
Discussion
To the best of our knowledge, this is the first study investigating the effect of cannabis use at neurochemical level in a representative sample of EP patients, comparing their nonusers counterpart and normative control population. Our main finding, which is in line with our principal hypothesis, is that cannabis use is significantly associated with decreased prefrontal Glu levels. Additional analyses also revealed that working memory performance was impaired in cannabis users as compared to non-users. Furthermore, our results go further and suggest that cannabis is implicated in the stronger Gludecline with age, with some relevance for the progression of the disease. Fig. 2 [Glu mPFC ] was lower in EP users comparing to both HC and EP non-users, while no differences were observed between EP non-users and controls. From left to right [Glu mPFC ] in healthy controls, EP non-users and EP users, respectively. Each horizontal bar indicates the mean value of the group. **P = .001; *P = .01 Our finding of reduced [Glu mPFC ] levels in EP users is consistent with the decreased Glu/Glx metabolite levels previously reported in the anterior cingulated-cortex (Muetzel et al. 2013; Prescot et al. 2013 ) and in basal ganglia (Chang et al. 2006; Prescot et al. 2011 ) of adolescent cannabis users. So far, only one study has been conducted in a cohort of early phase schizophrenia patients, reporting decreased frontal Glx levels in currently or past multi-substances users (Bernier et al. 2016) . Making comparisons across studies is difficult: firstly, the outcome measure vary between studies, involving Glx metabolite measurement for two studies (Muetzel et al. 2013; Bernier et al. 2016) and Glu metabolite measurement for the others (Chang et al. 2006; Prescot et al. 2011 Prescot et al. , 2013 . Secondly, the reference for quantification of Glu levels is different across studies; some studies using water (Prescot et al. 2011 (Prescot et al. , 2013 , while others use cerebrospinal fluid, total creatine, or phosphocreatine + creatine (Chang et al. 2006; Muetzel et al. 2013) . Discussing our findings is also complicated due to the lack of exhaustive evidence in the field. So far, only a few studies have focused on Glu-abnormalities in the frontal region before the full blown onset of the disorder (Treen et al. 2016) , in EP and established schizophrenia; with some evidence that glutamatergic variations might be sensitive to illness stage (Merritt et al. 2016) . It is well known, that the severity of symptoms associated with psychotic disorders typically evolves over time. Before the onset of a frank psychosis, subjects often present attenuated psychotic symptoms, usually showing a marked decline in social and occupational functioning, a clinical state referred to as Ultra High Risk (UHR) for psychotic disorder (Yung et al. 2005) . Starting from this prodromal phase, progressive changes in brain volume, including the PFC, and disturbances in Glu-neurotransmission (Marsman et al. 2013 ) may occur. Tibbo et al. (2004) found significantly higher levels of Glu in the right medial frontal lobe of HR compared to controls, although other studies failed to replicate these findings. Purdon et al. (2008) finding the absence of differences in Glu metabolites levels between HR and HC in the same brain region, as was for Yoo et al. (2009) . Concordantly, analyzing the medial-PFC in HR subjects, EP and schizophrenia patients, Natsubori et al. (2014) revealed significant decrease in Glu metabolites only in the schizophrenia group.
The decreased prefrontal Glu levels observed in EP users may be cautiously interpreted as the result of the interaction between cannabis usage and psychosis rather than the effect of illness itself, as no differences were detected between nonusers patients compared to controls. Moreover, the findings of a lack of Glu abnormalities in EP non-users may be explained in the light of those studies that did not show Glulevels decrease in the prefrontal region of EP patients, but consistently report such abnormalities in chronicity, as suggesting a role for cannabis use in driving the earlier onset of frontal Glu abnormalities. This needs however to be established in the context of a longitudinal study. The decrease of [Glu mPFC ] in our EP-users is intriguing and may be related to the behavioral changes observed in cannabis users. The glutamatergic system plays an important role in age-related cognitive decline and cognitive disorders, as tight regulation of Glu is essential for normal cognitive function (Rubino et al. 2015) . In particular, glutamatergic transmission, that controls recurrent excitation within PFC networks, is a crucial modulator for working memory (WM) (GoldmanRakic 1995) , by supporting retention of spatial information during the delay period of WM tasks (Deco and Rolls 2003) . Exogenous THC exposure induces spatial WM deficits, throughout a modulation of Glu release, whose molecular underpinnings could be the establishment of less synaptic contacts and/or less efficient synaptic connections, in those brain regions like PFC that have high density of CB1 receptors (Rubino et al. 2009 ). These abnormalities may be reflected at neurochemical level by the reduction of Glu concentration seen in our EP users. Consistently with these observations, LNS (Letter Number Span), a putative executive function working memory test requiring among others attention and temporary storage of information capacities (Twamley et al. 2006) , was the only neuropsychological test, albeit the limitation of the small sample size, which was impaired in EP users compared to non-users, and displayed a disrupted correlation to Glu concentration in cannabis users. Based on this background, the lack of a significant correlation between Glu levels and WM performance, observed in EP users, might probably stands for an alteration in WM signaling pathways, mediated by the reduced frontal glutamatergic tone related to cannabis use.
Counterintuitively, prior studies in EP demonstrated that subjects who used cannabis (especially those who used prior to age 16) performed better than non-using on global cognitive functioning, including WM. Moreover, these studies evidenced that the cognitive profile depends on the age at which regular cannabis use begins, and that comorbid cannabis use is associated with a superior cognitive profile only in schizophrenia-spectrum disorders but not in bipolar psychosis (Hanna et al. 2016) . We failed to replicate these observations, EP users displayed poorer performances in all neuropsychological domains explored, compared both to EP non-users and HC. In addition, age at which cannabis use started was not related to cognitive performances either. Probably this could be explained by the fact that our patients were late onset users, starting cannabis consuming on average at age 17, and heterogeneous in terms of diagnosis.
Current evidence has shown that Glu have also considerable potential as biomarker of disease progression (Brandt et al. 2016) , although the implications of changes in Glu on neuronal function are still not clear (Wijtenburg et al. 2015) . Given the tight metabolic relationship between glutamate and both NAA and Gln, changes in Glu levels that are not accompanied by NAA or Gln changes are surprising. NAA is an intermediate metabolite serving as a reservoir for replenishing Glu when necessary (Clark et al. 2006) . Similarly, Glu and Gln are metabolically coupled, as Glu is released into the synaptic cleft and rapidly transported into astroglia where it is enzymatically converted into Gln. Subsequently, Gln is shuttled back into neurons for conversion to Glu. Our finding of a diminished glutamatergic tone and of a greater Gludecline with age in EP users, without significant related changes in NAA or Gln (Supplementary material), is only partially in line with the results of the only existing study investigating Glu-metabolites in schizophrenia patients users (Bernier et al. 2016) . The authors found a reduction in Glx and mIns levels related to cannabis, alcohol, and methamphetamine use but failed to include patients without a lifetime history of substance use (non-users). Differences in both consuming behaviors (polysubstance vs cannabis use) and duration of illness between the studies may have probably accounted for these discrepancies.
Strengths and limitations
This study has a number of strengths. We have evaluated the role of cannabis in relation to brain neurochemical properties for the first time in a representative EP sample. The impact of cannabis substance used was studied independently of other substances. In addition, considering all our patients were in the early phase of psychosis, cannabis use had occurred prior to (or around) illness onset and not as a consequence of the illness. Also, patients were not exposed to long-term pharmacological treatment, making it unlikely that Glu alterations were due to antipsychotic medications. Moreover, when covarying for mean antipsychotic dosage, all our results retain their significance.
Several limitations must be noted. First of all, this study did not include a group of controls with a lifetime history of cannabis use, the real clinical-setting nature of the study might account for this. Moreover, the cross-sectional design, does not allow for a strong cause-effect interpretation of the findings. Furthermore, although other studies that have used self-report measures have also shown an association with brain structural alterations (Rigucci et al. 2016) , the lack of objective measures of cannabis use in our study is an important limitation. However, there is published evidence indicating that asking patients with psychosis about their use of cannabis is, at least in some situations, more accurate than, or as reliable as, urine or blood testing which can only provide information on recent use (Freeman et al. 2014) . The lack of a measure of the potency of cannabinoid compounds might nevertheless also affect the robustness of our findings; indeed, the recent changes in the composition of Bstreet^cannabis have created a new and complex landscape for the understanding the neurobiological impact of cannabis products. In line with the new tendencies in Europe, Switzerland cannabis drug market has recently changed, with an increased mean THC content both in resin and herbal strains (Data from the addiction monitoring in Switzerland, 2015, http://www.suchtmonitoring.ch). Future studies evaluating the effects of cannabis use on brain structure and function should therefore include a careful assessment of cannabis potency. Differences in paradigms used in MRS, such as magnetic field strength, may influence results and need to be considered when comparing results between studies. Separating glutamate and glutamine at lower field strengths being challenging, despite promising new approaches (Zhang and Shen 2016) , and despite studies at 7 T, having shown improved precision of glutamate measurement (Mekle et al. 2009 ) compared to lower field strengths, replication of these findings with an enhanced spectral sensitivity and resolution is needed.
In summary, our research which focused on prefrontal region revealed that cannabis use in the early phase of psychosis is associated with decreased Glu levels in the PFC and with a stronger Glu-decline with age, without significant changes in NAA or Gln. Our results suggest that cannabis might accelerate the progression of psychosis, which is seen at neurochemical levels with prefrontal Glu-abnormalities in EP users that normally are not found in the early stage of the illness.
